Clinical trials
Terminated trials in Norway
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
380 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 3 |
| 2002 | 3 |
| 2003 | 14 |
| 2004 | 10 |
| 2005 | 13 |
| 2006 | 17 |
| 2007 | 13 |
| 2008 | 15 |
| 2009 | 18 |
| 2010 | 10 |
| 2011 | 22 |
| 2012 | 12 |
| 2013 | 20 |
| 2014 | 22 |
| 2015 | 15 |
| 2016 | 15 |
| 2017 | 30 |
| 2018 | 25 |
| 2019 | 24 |
| 2020 | 24 |
| 2021 | 22 |
| 2022 | 10 |
| 2023 | 7 |
| 2024 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 380 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Norwegian University of Science and Technology | 36 |
| Oslo University Hospital | 36 |
| Haukeland University Hospital | 20 |
| Novartis Pharmaceuticals | 19 |
| St. Olavs Hospital | 14 |
| GlaxoSmithKline | 13 |
| AstraZeneca | 12 |
| Sanofi | 12 |
| Bayer | 10 |
| Hoffmann-La Roche | 10 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 13 |
| Heart Failure | 10 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Melanoma | 9 |
| Neoplasms | 9 |
| Breast Neoplasms | 8 |
| Stroke | 8 |
| Colitis, Ulcerative | 7 |
| Diabetes Mellitus, Type 1 | 7 |
| Neoplasm Metastasis | 7 |
Trials
Showing 1 to 25 of 380. Each trial links to its page on Pharma Observatory.
280 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.